Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan

In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% an...

Descripción completa

Detalles Bibliográficos
Autores principales: Arashiro, Takeshi, Arima, Yuzo, Kuramochi, Jin, Muraoka, Hirokazu, Sato, Akihiro, Chubachi, Kumi, Yanai, Atsushi, Arioka, Hiroko, Uehara, Yuki, Ihara, Genei, Kato, Yasuyuki, Yanagisawa, Naoki, Ueda, Akihiro, Kato, Hideaki, Oka, Hideaki, Nishida, Yusuke, Nidaira, Yuki, Asami, Takahiro, Jinta, Torahiko, Nakamura, Akira, Oba, Kunihiro, Taniyama, Daisuke, Yamamoto, Kei, Tanaka, Katsushi, Ueshima, Kankuro, Fuwa, Tetsuji, Stucky, Ashley, Suzuki, Tadaki, Smith, Chris, Hibberd, Martin, Ariyoshi, Koya, Suzuki, Motoi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284337/
https://www.ncbi.nlm.nih.gov/pubmed/37351451
http://dx.doi.org/10.1093/ofid/ofad240
Descripción
Sumario:In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined).

Ejemplares similares